Details of the Drug

General Information of Drug (ID: DM9RBUZ)

Drug Name

MB-106

Indication

Disease Entry	ICD 11	Status	REF
B-cell non-hodgkin lymphoma	2B33.5	Phase 1/2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

References

1	ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas